- Home
- MRNA vs ONC Comparison
MRNA vs ONC Comparison
Compare MRNA & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | ONC |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 31.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRNA | ONC |
|---|---|---|
| Price | $72.47 | $290.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $34.27 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 7.6M | 286.3K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $9.36 | $723.76 |
| Revenue Next Year | $15.43 | $15.04 |
| P/E Ratio | ★ N/A | $614.06 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $240.00 |
| 52 Week High | $73.28 | $385.22 |
Technical Indicators
Market Signals| Indicator | MRNA | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 74.31 | 58.39 |
| Support Level | $45.69 | $289.57 |
| Resistance Level | N/A | $310.50 |
| Average True Range (ATR) | 5.14 | 7.72 |
| MACD | 1.66 | 3.65 |
| Stochastic Oscillator | 92.36 | 93.46 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.